KoBioLabs (A348150) Stock Overview
Provides microbiome therapeutics for metabolic, immune, and brain diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A348150 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
KoBioLabs, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,590.00 |
| 52 Week High | ₩8,730.00 |
| 52 Week Low | ₩2,850.00 |
| Beta | 0.12 |
| 1 Month Change | -5.03% |
| 3 Month Change | -31.09% |
| 1 Year Change | -24.58% |
| 3 Year Change | -64.80% |
| 5 Year Change | -89.27% |
| Change since IPO | -88.53% |
Recent News & Updates
KoBioLabs, Inc's (KOSDAQ:348150) Shares Leap 26% Yet They're Still Not Telling The Full Story
KoBioLabs, Inc ( KOSDAQ:348150 ) shareholders would be excited to see that the share price has had a great month...Is KoBioLabs (KOSDAQ:348150) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Market Might Still Lack Some Conviction On KoBioLabs, Inc (KOSDAQ:348150) Even After 36% Share Price Boost
The KoBioLabs, Inc ( KOSDAQ:348150 ) share price has done very well over the last month, posting an excellent gain of...Recent updates
Shareholder Returns
| A348150 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.5% | 4.5% | -3.6% |
| 1Y | -24.6% | 6.9% | 148.4% |
Return vs Industry: A348150 underperformed the KR Biotechs industry which returned 6.9% over the past year.
Return vs Market: A348150 underperformed the KR Market which returned 148.4% over the past year.
Price Volatility
| A348150 volatility | |
|---|---|
| A348150 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in KR Market | 16.5% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A348150 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A348150's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Han Seung Lee | kobiolabs.com |
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea.
KoBioLabs, Inc Fundamentals Summary
| A348150 fundamental statistics | |
|---|---|
| Market cap | ₩69.71b |
| Earnings (TTM) | -₩3.73b |
| Revenue (TTM) | ₩71.21b |
Is A348150 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A348150 income statement (TTM) | |
|---|---|
| Revenue | ₩71.21b |
| Cost of Revenue | ₩18.72b |
| Gross Profit | ₩52.49b |
| Other Expenses | ₩56.22b |
| Earnings | -₩3.73b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -191.98 |
| Gross Margin | 73.71% |
| Net Profit Margin | -5.24% |
| Debt/Equity Ratio | 34.6% |
How did A348150 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 01:44 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KoBioLabs, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.